30,021 Shares in Certara, Inc. $CERT Acquired by Dynamic Technology Lab Private Ltd

Key Points

• Dynamic Technology Lab Private Ltd acquired a new stake in Certara, Inc., purchasing 30,021 shares valued at approximately $297,000 in the first quarter.
• Following the acquisition, institutional investors now own 73.96% of Certara's stock, indicating strong institutional confidence in the company.
• Certara recently reported quarterly earnings, missing the consensus EPS estimate, but showing a 12.1% annual revenue increase, with a market cap of $1.81 billion.

Dynamic Technology Lab Private Ltd purchased a new stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 30,021 shares of the company's stock, valued at approximately $297,000.

Several other institutional investors and hedge funds have also made changes to their positions in CERT. Versant Capital Management Inc raised its stake in Certara by 218.8% in the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock worth $27,000 after acquiring an additional 1,866 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Certara in the first quarter valued at about $31,000. AlphaQuest LLC purchased a new position in shares of Certara in the first quarter worth about $39,000. Quarry LP acquired a new stake in shares of Certara during the first quarter worth about $98,000. Finally, Associated Banc Corp purchased a new stake in Certara in the first quarter valued at approximately $101,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on CERT shares. UBS Group cut their price objective on shares of Certara from $17.50 to $15.00 and set a "buy" rating on the stock in a research note on Thursday, August 7th. Morgan Stanley started coverage on shares of Certara in a research note on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 target price on the stock. Zacks Research raised shares of Certara from a "strong sell" rating to a "hold" rating in a research note on Friday, September 5th. Finally, KeyCorp cut their price objective on Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. Five equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $15.14.

Insider Buying and Selling

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the business's stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total value of $559,366.08. Following the completion of the transaction, the insider owned 73,979 shares in the company, valued at $807,850.68. The trade was a 40.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 2.33% of the stock is owned by corporate insiders.

Certara Trading Up 2.4%

CERT traded up $0.28 during mid-day trading on Thursday, hitting $11.79. 1,526,241 shares of the stock were exchanged, compared to its average volume of 1,441,672. The firm's fifty day moving average is $10.75 and its two-hundred day moving average is $11.27. Certara, Inc. has a 1-year low of $8.64 and a 1-year high of $15.69. The company has a market cap of $1.89 billion, a PE ratio of 235.85 and a beta of 1.43. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Certara had a return on equity of 5.11% and a net margin of 1.97%.The business had revenue of $104.57 million for the quarter, compared to analysts' expectations of $104.14 million. During the same quarter last year, the company earned $0.07 earnings per share. The firm's revenue for the quarter was up 12.1% on a year-over-year basis. Equities analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.